

ADULT Medication Monograph

GLIBENCLAMIDE

This document should be read in conjunction with this **DISCLAIMER**

Formulary: Unrestricted

Class	Sulfonylurea		
Presentation	Tablet: 5mg		
Storage	Store at room temperature, below 25°C		
Dose	Type 2 diabetes Oral: 2.5mg-20mg daily in 1 or 2 doses (up to 10mg as single dose). Maximum daily dose 15mg if 12-18 years		
Administration	Oral With or soon after food to avoid hypoglycaemia		
Pregnancy	1 st Trimester: Monitoring required 2 nd Trimester: Monitoring required 3 rd Trimester: Monitoring required For more information, please contact KEMH Obstetric Medicines Information Service.		
Breastfeeding	Considered safe to use. From the limited information available, glibenclamide has not been detected in breast milk and hypoglycaemia has not been observed in breastfed infants of women taking glibenclamide. Women who choose to breastfed their healthy full term infant while taking glibenclamide should observe the infant for signs of hypoglycaemia. For more information, please contact KEMH Obstetric Medicines Information Service.		
Monitoring	Blood glucose level, HbA1c		
Clinical Guidelines and Policies	KEMH Clinical Guideline: <u>Diabetes</u>		

	KEMH Pharmaceutical & Medicines Management Guidelines:			
	KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration			
	Pre-operative Medication Management			
References	Australian Medicines Handbook. Glibenclamide. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Apr 7]. Available from: https://amhonline.amh.net.au/			
	The Royal Women's Hospital. Glibenclamide. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2020 Apr 7]. Available from: https://thewomenspbmg.org.au			

Keywords:	Glibenclamide, Diabetes, Hypoglycaemic agents, T2DM				
Publishing:					
Document owner:	Chief Pharmacist				
Author / Reviewer:	KEMH Pharmacy Department				
Date first issued:	January 2015	Version:	4.0		
Last reviewed:	May 2020	Next review date:	May 2023		
Endorsed by:	Medicines and Therapeutics Committee	Date:	Jan 2015		
Standards Applicable:	NSQHS Standards: 1 Governance, 4 Medication Safety				

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020